Search the Newsreel

Form 4 Adaptive Biotechnologies Corp For: 3 August By Investing.com

This article from Investing.com announces the filing of Form 4 for Adaptive Biotechnologies Corp on August 3rd. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol …

Adaptive Biotechnologies (NASDAQ: ADPT) CCO trades 1,299 shares under plan

Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 1,299 shares of common stock on July 30, 2026, at $24.00 per share, totaling $31,176. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, Bobulsky …

Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer

Rainer Blair to retire WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, …

AdaptHealth Corp. Q2 2026 Earnings Preview

* AdaptHealth Corp. (AHCO [https://seekingalpha.com/symbol/AHCO]) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. * The consensus EPS Estimate is $0.17 [https://seekingalpha.com/symbol/AHCO/earnings/estimates] (+70.0% Y/Y) and the consensus Revenue Estimate is $846.77M (+5.8% Y/Y). * Over the last 3 months, …

AdaptHealth (AHCO) Reports Earnings Tomorrow: What To Expect

AdaptHealth (AHCO) is set to report earnings tomorrow before market hours, with analysts expecting a 5.9% year-on-year revenue growth. The company previously beat revenue expectations but missed EPS estimates. Peers in the senior health segment, BrightSpring Health Services and Chemed, have already reported strong …

Danaher ernennt neue CEO und bestätigt Prognose: Aktie legt zu

Should Flat Sales And Earnings Dilution Require Action From AdaptHealth (AHCO) Investors?

Adaptive Biotechnologies (ADPT) Raised MRD Guidance, Is The Stock Fairly Valued?

5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX

(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained long-term value, rather than chasing numerous average investments. …

Adaptive Biotechnologies Corporation Revenue Breakdown – NASDAQ:ADPT

Adaptive Biotechnologies Corp (ADPT) Shares Fall 6.7% -- GF Value Says Still Overvalued

Adaptive Biotechnologies Corp (ADPT) shares dropped 6.7%, and GuruFocus's GF Value suggests the stock is 125.0% overvalued at $22.57 compared to its estimated fair value of $10.03. Despite an above-average GF Score of 66/100, driven by strong growth and momentum ranks, its financial strength …

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 14.1% over the past month. The stock hit a new 52-week high of $24.34 in the previous session. Adaptive Biotechnologies has gained 48.9% since the start of the year compared …

Adaptive Biotechnologies Corp (ADPT) Institutional Confidence

The article discusses the institutional confidence score for Adaptive Biotechnologies Corp (ADPT), which is currently 10.00, ranking it 1st in the Biotechnology & Medical Research industry. Institutional shareholding stands at 94.68%, with a slight quarter-over-quarter decrease. Andreas Halvorsen is highlighted as the largest institutional …

Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Indaptus Therapeutics Inc (INDP), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. The stock is currently trading between a resistance level of 2.63 and a support level of 0.82, …

Adaptive Biotechnologies (NASDAQ: ADPT) insider reports Rule 10b5-1 stock sales

Adaptive Biotechnologies insider Susan Bobulsky has filed planned stock sales under a Rule 10b5-1 trading plan. The Form 144 filing details multiple open-market sales of common shares on NASDAQ in June and July 2026, totaling 26,487 shares for proceeds of $521,214.00. The sales are …

Adaptive Biotechnologies Number of Employees 2026 | Employee Count & Headcount Data

Adaptive Biotechnologies (NASDAQ: ADPT) had approximately 632 employees worldwide as of March 2026, a decline of 18.7% from 777 employees in 2023. Despite the overall headcount decline, the company is actively hiring, with 53 active job postings in 2026, a 40.9% increase from 2025. …

Adaptive Biotechnologies stock hits 52-week high at 23.25 USD

Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $23.25, reflecting a significant 120.31% increase over the past year. Despite its robust revenue growth of 56% over the last twelve months, InvestingPro analytical data suggests the stock might be overvalued. Recent Q2 results showed …

Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Indaptus Therapeutics Inc (INDP), noting its current valuation score is 6.27, ranking 316 out of 385 in its industry. The company's P/E ratio is -0.10, which is significantly below its recent high and above its recent low. …

Adaptive Biotechnologies Q2 Net Loss Widens Despite Revenue Growth; Stock Down

(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss amid revenue growth. In addition, the company also provided an update on its full-year 2026 revenue outlook for …

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

This article first appeared on GuruFocus. Total Revenue: $71.6 million, up 30% year-over-year. MRD Revenue: $66.2 million, up 33% year-over-year; core MRD revenue (excluding milestones) grew 49%. Clinical Revenue (MRD): Increased 53% year-over-year, driven by a 43% increase in testing volumes and a 7% …

Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Adaptive Biotechnologies Corp (AD

ETFs Investing in Adaptive Biotechnologies Corp. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (A2PLR5). It provides detailed financial data for each ETF, including market value, weight of Adaptive Biotechnologies stock, issuer, management style, focus, expense ratio, AUM, price change, and 3-year NAV …

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) reported $71.55 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 21.5%. EPS of -$0.10 for the same period compares to -$0.17 a year ago. The reported revenue represents a surprise of +7.98% over the Zacks …

Adaptive Biotechnologies (ADPT) Releases Q2 2026 Earnings: Revenue Growth but Still Unprofitable

Adaptive Biotechnologies (ADPT) reported Q2 2026 revenues of $71.6 million, marking a 21.5% year-over-year increase and surpassing analyst estimates. Despite this revenue growth and improved gross profit, the company remained unprofitable, posting a net loss of $39.8 million. Insider trading data shows significant sales …

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results …

Adaptive Biotechnologies' MRD Business Grew 33%; clonoSEQ Volume Reached 36,111

Adaptive Biotechnologies (ADPT) reported strong Q2 2026 financial results, with overall revenue up 22% to $71.6 million, largely driven by its Minimal Residual Disease (MRD) business, which grew 33% year-over-year. The company also announced plans to separate its MRD and Immune Medicine businesses, completed …

Adaptive Biotechnologies (Nasdaq: ADPT) boosts MRD 2026 guidance after Q2 revenue hits $71.6M

Adaptive Biotechnologies (ADPT) announced strong second-quarter 2026 results, with total revenue reaching $71.6 million, a 22% year-over-year increase, primarily driven by its Minimal Residual Disease (MRD) segment which grew 33%. The company raised its full-year 2026 MRD revenue guidance to $268–$278 million and completed …

Cardinal Health (CAH) Stock Looks Pricey Following Its Home Care Deal Push

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Cardinal Health stock has delivered a very strong 334.8% return over the past five years, yet its current checks lean expensive and suggest the recent share price …

Adaptive Biotechnologies: Q2 Earnings Snapshot

This article provides an earnings snapshot for Adaptive Biotechnologies (NASDAQ: ADPT) for its second quarter. The content appears to be a placeholder or an incomplete article, as it lacks any financial data, results, or detailed information beyond the title.

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

AHCO Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of Adapthealth Corp (AHCO), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company primarily generates revenue from Insurance (58.8%), with other significant streams coming from Government and Patient Pay. AHCO's gross margin is 12.37%, …

Discipline and Rules-Based Execution in AHCO Response

This article analyzes Adapthealth Corp. (NASDAQ: AHCO) with AI models, identifying a weak near-term sentiment but strong mid- and long-term outlooks. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing specific entry, target, and stop-loss levels for each. …

AdaptHealth Corp. (AHCO) Stock Report: A 29% Upside Potential With Strong Buy Ratings

AdaptHealth Corp. (AHCO), a key player in the medical devices industry with a market cap of $1.49 billion, offers significant growth potential as indicated by a forward P/E of 9.40. Despite current profitability challenges, the company boasts strong operational efficiency with $267.9 million in …

AdaptHealth (AHCO) to Release Quarterly Earnings on Tuesday

INDP|Indaptus Therapeutics Inc|Price:2.100|Chg%:+0.060

This article provides a comprehensive stock analysis of Indaptus Therapeutics Inc (INDP) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry, despite recent weak stock market performance. The analysis also covers institutional …

Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Indaptus Therapeutics Inc (INDP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It highlights the company's current stock price, market capitalization, and a significant daily percentage …